Department of Psychiatry, Pomeranian Medical University, ul. Broniewskiego 26, 71-460 Szczecin, Poland.
Department of Pharmacology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Psychiatry Res. 2014 Oct 30;219(2):261-7. doi: 10.1016/j.psychres.2014.05.039. Epub 2014 Jun 2.
The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in paranoid schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. One-hundred and ninety-one Polish patients suffering from paranoid schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms (EPS)) was measured at baseline and after 12 weeks of antipsychotic treatment. After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of EPS. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. The selected polymorphisms are not primarily involved in changes in body weights and EPS related to antipsychotic treatment in paranoid schizophrenia patients.
本研究的主要目的是评估多巴胺能、5-羟色胺能和谷氨酸能系统相关基因与偏执型精神分裂症患者抗精神病治疗后不良事件之间的可能关联。研究的第二个目的是比较非典型（齐拉西酮和奥氮平）和典型（奋乃静）抗精神病药物之间这些症状的强度。191 名患有偏执型精神分裂症的波兰患者接受了 DRD2、DAT1、COMT、MAOA、SERT、5HT2A 和 GRIK3 多态性的基因分型。患者被随机分配接受奋乃静、奥氮平或齐拉西酮单药治疗 3 个月。在基线和抗精神病治疗 12 周后测量副作用（体重和锥体外系症状（EPS）的变化）的强度。治疗 3 个月后，奥氮平治疗组体重增加最大，齐拉西酮治疗组体重增加最小。未发现任何研究的基因多态性与体重变化有关。奋乃静治疗与 EPS 强度显著升高有关。未发现任何研究的多态性与抗精神病治疗后锥体外系不良事件的变化有关。所选多态性与偏执型精神分裂症患者抗精神病治疗相关的体重和 EPS 变化无关。
